|Last Price$55.70||Day Change (%)-0.16%|
|Open Price$55.53||Day Change ($)-0.09|
|Day Range55.27–56.02||52-Week Range43.51–57.65|
As of Fri 03/14/2014 04:00 PM EST | USD
Good day, everyone, and welcome to Merck's Fourth Quarter 2013 Earnings Call. Today's call is being recorded.
Hologic Enhances Executive Leadership Structure to Drive Global Growth and Improve Operational Execution
Research and Markets: Concise Analysis of the International Orphan Drugs Industry
Regado Biosciences Announces Year-End 2013 Financial Results and Corporate Highlights
Merck KGaA Profit Lifted by Cost Savings
Access Pharmaceuticals Announces MuGard License Agreement With Hanmi Pharmaceutical In Korea
Havas Worldwide Names Rich Rosenthal To New Post Of North America Head Of Content
Alnylam Announces Closing of Previously Announced Alliance with Genzyme for Discovery, Development, and Commercialization of RNAi Therapeutics as Genetic Medicines
Merck MRK announced Tuesday that Januvia for Type 2 diabetes received Food and Drug Administration approval. While we think Januvia is an important advance in diabetes treatment, we're not changing our fair value estimate for Merck , as we had already incorporated sales from the drug into our model. ...
Merck MRK suffered a couple of blows Thursday in the Vioxx litigation fight, but we're not changing our fair value estimate. A New Orleans jury awarded $51 million to a plaintiff who suffered a heart attack while on Vioxx, and a judge in New Jersey vacated a verdict that had previously come down in ...